Second primary malignancies in ruxolitinib-treated myelofibrosis: real-world evidence from 219 consecutive patients
-
- Margherita Maffioli
- Hematology Unit, Ospedale di Circolo, ASST Sette Laghi, Varese, Italy;
-
- Toni Giorgino
- Biophysics Institute (IBF-CNR), National Research Council of Italy, Milan, Italy;
-
- Barbara Mora
- Hematology Unit, Ospedale di Circolo, ASST Sette Laghi, Varese, Italy;
-
- Alessandra Iurlo
- Hematology Division, Foundation Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy;
-
- Elena Elli
- Hematology Division and Bone Marrow Unit, Ospedale San Gerardo, Monza, Italy;
-
- Maria Chiara Finazzi
- Department of Hematology, ASST Papa Giovanni XXIII, Bergamo, Italy;
-
- Marianna Caramella
- Department of Hematology, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy;
-
- Elisa Rumi
- Department of Molecular Medicine, University of Pavia, Pavia, Italy;
-
- Maria Cristina Carraro
- Hematology and Transfusional Medicine Unit, ASST Fatebenefratelli Sacco, Milan, Italy;
-
- Nicola Polverelli
- Unit of Blood Diseases and Stem Cell Transplantation, ASST Spedali Civili di Brescia, Brescia, Italy;
-
- Mariella D’Adda
- Department of Hematology, ASST Spedali Civili di Brescia, Brescia, Italy;
-
- Simona Malato
- Hematology and Bone Marrow Transplantation Unit, San Raffaele Scientific Institute, Milan, Italy;
-
- Marianna Rossi
- Department of Hematology, Cancer Center, IRCCS Humanitas Research Hospital/Humanitas University, Rozzano, Italy;
-
- Alfredo Molteni
- Hematology Unit, ASST Cremona, Cremona, Italy;
-
- Alessandro Vismara
- Onco-Hematology Unit, ASST-Rhodense, Rho, Italy;
-
- Cinzia Sissa
- Department of Hematology and Transfusion Medicine, ASST Mantova, Mantova, Italy;
-
- Francesco Spina
- Hematology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy;
-
- Michela Anghilieri
- Oncology Department, ASST Lecco, Lecco, Italy;
-
- Daniele Cattaneo
- Hematology Division, Foundation Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy;
-
- Rossella Renso
- Hematology Division and Bone Marrow Unit, Ospedale San Gerardo, Monza, Italy;
-
- Marta Bellini
- Department of Hematology, ASST Papa Giovanni XXIII, Bergamo, Italy;
-
- Maria Luisa Pioltelli
- Department of Hematology, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy;
-
- Chiara Cavalloni
- Department of Molecular Medicine, University of Pavia, Pavia, Italy;
-
- Daniela Barraco
- Hematology Unit, Ospedale di Circolo, ASST Sette Laghi, Varese, Italy;
-
- Raffaella Accetta
- Cytogenetics and Genetics Laboratory, Ospedale di Circolo, ASST Sette Laghi, Varese, Italy; and
-
- Lorenza Bertù
- Department of Medicine and Surgery, University of Insubria, ASST Sette Laghi–Ospedale di Circolo, Varese, Italy
-
- Matteo Giovanni Della Porta
- Department of Hematology, Cancer Center, IRCCS Humanitas Research Hospital/Humanitas University, Rozzano, Italy;
-
- Francesco Passamonti
- Department of Medicine and Surgery, University of Insubria, ASST Sette Laghi–Ospedale di Circolo, Varese, Italy
抄録
<jats:title>Key Points</jats:title><jats:p>We present real-world data on all ruxolitinib-treated myelofibrosis patients in a 10-million-resident region, with a follow-up of 2 years. We found no evidence of an increased risk of developing lymphomas.</jats:p>
収録刊行物
-
- Blood Advances
-
Blood Advances 3 (21), 3196-3200, 2019-10-28
American Society of Hematology